Functional & Integrative GenomicsGenomicsPeer-reviewed journal article
MyeloDB: A multi-omics resource for Multiple Myeloma
Ambuj KumariD, Keerthana Vinod Kumar, Kavita KundaliD, Avik SenguptaiD, Simran SharmaiD, R Kunjulakshmi, Rahul KumariD
Abstract
Multiple myeloma (MM) is a common type of blood cancer affecting plasma cells originating from the lymphoid B-cell lineage. It accounts for about 10% of all haematological malignancies and can cause significant end-organ damage. The emergence of genomic technologies such as next-generation sequencing and gene expression analysis has opened new possibilities for early detection of multiple myeloma and identification of personalized treatment options. However, there remain significant challenges to overcome in MM research, including integrating multi-omics data, achieving a comprehensive understanding of the disease, and developing targeted therapies and biomarkers. The extensive data generated by these technologies presents another challenge for data analysis and interpretation. To bridge this gap, we have developed a multi-omics open-access database called MyeloDB. It includes gene expression profiling, high throughput CRISPR-Cas9 screens, drug sensitivity resources profile, and biomarkers. MyeloDB contains 47 expression profiles, 3 methylation profiles comprising a total of 5630 patient samples and 15 biomarkers which were reported in previous studies. In addition to this, MyeloDB can provide significant insight of gene mutations in MM on drug sensitivity. Furthermore, users can download the datasets and conduct their own analyses. Utilizing this database, we have identified five novel genes i.e., CBFB, MANF, MBNL1, SEPHS2 and UFM1 as potential drug targets for MM. We hope MyeloDB will serve as a comprehensive platform for researchers and foster novel discoveries in MM. MyeloDB is freely accessible at: (https://project.iith.ac.in/cgntlab/myelodb/)
- organism: human
- assay: bulk RNA-seq
- assay: DNA methylation
- research focus: database / resource
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 4
- FWCI
- 1.24
- Field percentile
- top 22%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- AMLdb: A comprehensive multi-omics platform to understand the pathogenesis and discover biomarkers for acute myeloid leukemia
Keerthana Vinod Kumar, Ambuj Kumar, … Rahul Kumar·bioRxiv·May 19, 2023
- Translating multi-omics complexity into sparse prognostic biomarkers for multiple myeloma
Benedikt Obermayer, Manuela Benary, … Dieter Beule·bioRxiv·Aug 21, 2026
- Integrative multi-omics identifies high risk Multiple Myeloma segment associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways
M. Ortiz Estevez, M. Samur, … A. Thakurta·bioRxiv·Sep 3, 2021
- Identification of biomarkers and candidate inhibitors for multiple myeloma
Hanming Gu, Wei Wang, Gongsheng Yuan·bioRxiv·Feb 25, 2021
- Stage-specific gene ratios highlight genes and mechanisms related to presymptomatic and symptomatic Multiple Myeloma
Grigoris Georgiou, George Minadakis, … George M. Spyrou·bioRxiv·Nov 4, 2024
- A Comprehensive Targeted Panel of 295 Genes: Unveiling Key Disease Initiating and Transformative Biomarkers in MultipleMyeloma
Vivek Ruhela, Ritu Gupta, … Anubha Gupta·Computers in Biology and MedicinePeer-reviewed·Jul 6, 2025